306 related articles for article (PubMed ID: 27140825)
1. Spotlight on Volasertib: Preclinical and Clinical Evaluation of a Promising Plk1 Inhibitor.
Van den Bossche J; Lardon F; Deschoolmeester V; De Pauw I; Vermorken JB; Specenier P; Pauwels P; Peeters M; Wouters A
Med Res Rev; 2016 Jul; 36(4):749-86. PubMed ID: 27140825
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and mechanism of action of volasertib, a potent and selective inhibitor of Polo-like kinases, in preclinical models of acute myeloid leukemia.
Rudolph D; Impagnatiello MA; Blaukopf C; Sommer C; Gerlich DW; Roth M; Tontsch-Grunt U; Wernitznig A; Savarese F; Hofmann MH; Albrecht C; Geiselmann L; Reschke M; Garin-Chesa P; Zuber J; Moll J; Adolf GR; Kraut N
J Pharmacol Exp Ther; 2015 Mar; 352(3):579-89. PubMed ID: 25576074
[TBL] [Abstract][Full Text] [Related]
3. Thoughts on the current assessment of Polo-like kinase inhibitor drug discovery.
Strebhardt K; Becker S; Matthess Y
Expert Opin Drug Discov; 2015 Jan; 10(1):1-8. PubMed ID: 25263688
[TBL] [Abstract][Full Text] [Related]
4. In vitro study of the Polo-like kinase 1 inhibitor volasertib in non-small-cell lung cancer reveals a role for the tumor suppressor p53.
Van den Bossche J; Deben C; De Pauw I; Lambrechts H; Hermans C; Deschoolmeester V; Jacobs J; Specenier P; Pauwels P; Vermorken JB; Peeters M; Lardon F; Wouters A
Mol Oncol; 2019 May; 13(5):1196-1213. PubMed ID: 30859681
[TBL] [Abstract][Full Text] [Related]
5. Current clinical trials with polo-like kinase 1 inhibitors in solid tumors.
Yim H
Anticancer Drugs; 2013 Nov; 24(10):999-1006. PubMed ID: 23949254
[TBL] [Abstract][Full Text] [Related]
6. Polo-like Kinase Inhibitor Volasertib Exhibits Antitumor Activity and Synergy with Vincristine in Pediatric Malignancies.
Abbou S; Lanvers-Kaminsky C; Daudigeos-Dubus E; LE Dret L; Laplace-Builhe C; Molenaar J; Vassal G; Geoerger B;
Anticancer Res; 2016 Feb; 36(2):599-609. PubMed ID: 26851014
[TBL] [Abstract][Full Text] [Related]
7. Plk1 Inhibitors in Cancer Therapy: From Laboratory to Clinics.
Gutteridge RE; Ndiaye MA; Liu X; Ahmad N
Mol Cancer Ther; 2016 Jul; 15(7):1427-35. PubMed ID: 27330107
[TBL] [Abstract][Full Text] [Related]
8. BI_2536--targeting the mitotic kinase Polo-like kinase 1 (Plk1).
Wäsch R; Hasskarl J; Schnerch D; Lübbert M
Recent Results Cancer Res; 2010; 184():215-8. PubMed ID: 20072841
[TBL] [Abstract][Full Text] [Related]
9. Human ATP-Binding Cassette Transporter ABCB1 Confers Resistance to Volasertib (BI 6727), a Selective Inhibitor of Polo-like Kinase 1.
Wu CP; Hsieh CH; Hsiao SH; Luo SY; Su CY; Li YQ; Huang YH; Huang CW; Hsu SC
Mol Pharm; 2015 Nov; 12(11):3885-95. PubMed ID: 26412161
[TBL] [Abstract][Full Text] [Related]
10. A phase I study of two dosing schedules of volasertib (BI 6727), an intravenous polo-like kinase inhibitor, in patients with advanced solid malignancies.
Lin CC; Su WC; Yen CJ; Hsu CH; Su WP; Yeh KH; Lu YS; Cheng AL; Huang DC; Fritsch H; Voss F; Taube T; Yang JC
Br J Cancer; 2014 May; 110(10):2434-40. PubMed ID: 24755882
[TBL] [Abstract][Full Text] [Related]
11. Small molecule inhibition of polo-like kinase 1 by volasertib (BI 6727) causes significant melanoma growth delay and regression in vivo.
Cholewa BD; Ndiaye MA; Huang W; Liu X; Ahmad N
Cancer Lett; 2017 Jan; 385():179-187. PubMed ID: 27793694
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic polo-like kinase 1 inhibition results in mitotic arrest and subsequent cell death of blasts in the bone marrow of AML patients and has similar effects in non-neoplastic cell lines.
Münch C; Dragoi D; Frey AV; Thurig K; Lübbert M; Wäsch R; Bogatyreva L; Hauschke D; Lassmann S; Werner M; May AM
Leuk Res; 2015 Apr; 39(4):462-70. PubMed ID: 25697066
[TBL] [Abstract][Full Text] [Related]
13. The role of Plk3 in oncogenesis.
Helmke C; Becker S; Strebhardt K
Oncogene; 2016 Jan; 35(2):135-47. PubMed ID: 25915845
[TBL] [Abstract][Full Text] [Related]
14. Initial testing (stage 1) of the Polo-like kinase inhibitor volasertib (BI 6727), by the Pediatric Preclinical Testing Program.
Gorlick R; Kolb EA; Keir ST; Maris JM; Reynolds CP; Kang MH; Carol H; Lock R; Billups CA; Kurmasheva RT; Houghton PJ; Smith MA
Pediatr Blood Cancer; 2014 Jan; 61(1):158-64. PubMed ID: 23956067
[TBL] [Abstract][Full Text] [Related]
15. Phase I trial of volasertib, a Polo-like kinase inhibitor, plus platinum agents in solid tumors: safety, pharmacokinetics and activity.
Awada A; Dumez H; Aftimos PG; Costermans J; Bartholomeus S; Forceville K; Berghmans T; Meeus MA; Cescutti J; Munzert G; Pilz K; Liu D; Schöffski P
Invest New Drugs; 2015 Jun; 33(3):611-20. PubMed ID: 25794535
[TBL] [Abstract][Full Text] [Related]
16. Polo-like kinase 1 (Plk1) as a novel drug target in chronic myeloid leukemia: overriding imatinib resistance with the Plk1 inhibitor BI 2536.
Gleixner KV; Ferenc V; Peter B; Gruze A; Meyer RA; Hadzijusufovic E; Cerny-Reiterer S; Mayerhofer M; Pickl WF; Sillaber C; Valent P
Cancer Res; 2010 Feb; 70(4):1513-23. PubMed ID: 20145140
[TBL] [Abstract][Full Text] [Related]
17. PLK1 inhibitors: setting the mitotic death trap.
Plyte S; Musacchio A
Curr Biol; 2007 Apr; 17(8):R280-3. PubMed ID: 17437704
[TBL] [Abstract][Full Text] [Related]
18. Discovery and development of the Polo-like kinase inhibitor volasertib in cancer therapy.
Gjertsen BT; Schöffski P
Leukemia; 2015 Jan; 29(1):11-9. PubMed ID: 25027517
[TBL] [Abstract][Full Text] [Related]
19. Radiosensitization in esophageal squamous cell carcinoma: Effect of polo-like kinase 1 inhibition.
Chen JL; Chen JP; Huang YS; Tsai YC; Tsai MH; Jaw FS; Cheng JC; Kuo SH; Shieh MJ
Strahlenther Onkol; 2016 Apr; 192(4):260-8. PubMed ID: 26952039
[TBL] [Abstract][Full Text] [Related]
20. Combined gene expression profiling and RNAi screening in clear cell renal cell carcinoma identify PLK1 and other therapeutic kinase targets.
Ding Y; Huang D; Zhang Z; Smith J; Petillo D; Looyenga BD; Feenstra K; Mackeigan JP; Furge KA; Teh BT
Cancer Res; 2011 Aug; 71(15):5225-34. PubMed ID: 21642374
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]